Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...
Clinical Trials Arena on MSN
Breye Therapeutics’ oral retinopathy drug shows early improvement in disease activity
Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib study.
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4) inhibitors in ...
MedPage Today on MSN
Dual GIP/GLP-1 drug linked to reduced diabetic retinopathy incidence
However, concerns about the impact of rapid glycemic control on diabetic retinopathy risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results